Literature DB >> 8132364

Short term treatment of visceral leishmaniasis of the Old World with low dose interferon gamma and pentavalent antimony.

J van Lunzen1, P Kern, J Schmitz, J Brzoska, S Flessenkämper, M Dietrich.   

Abstract

Eight adult patients with visceral leishmaniasis acquired in mediterranean countries were treated in a prospective study with a combined immunomodulating and antiparasitic regimen consisting of low-dose interferon-gamma (IFN-gamma) and pentavalent antimony. The clinical outcome, hematological and parasitological parameters, the duration of treatment and number of treatment cycles as well as the cumulative dose of pentavalent antimony applied, have been evaluated. The combined treatment led to complete resolution of symptoms and parasitological cure in all cases of visceral leishmaniasis without major side effects. Combined treatment resulted in a significant reduction of duration of treatment (19 vs. 31 days, p < 0.02) and cumulative dose of pentavalent antimony (11.67 vs. 19.30 g, p < 0.02) compared to historical controls (n = 6). No relapses occurred after a median follow-up of 9 months (range: 2-28 months). We conclude that combination therapy is tolerated well and is highly effective in patients with visceral leishmaniasis. The addition of IFN-gamma to standard therapy with pentavalent antimony may reduce the cumulative dose of antimonial drugs, shortens the treatment period and probably reduces the number of relapses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8132364     DOI: 10.1007/bf01728914

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

1.  Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.

Authors:  R Badaro; E Falcoff; F S Badaro; E M Carvalho; D Pedral-Sampaio; A Barral; J S Carvalho; M Barral-Netto; M Brandely; L Silva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

2.  Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine.

Authors:  A D Bryceson; J D Chulay; M Mugambi; J B Were; G Gachihi; C N Chunge; R Muigai; S M Bhatt; M Ho; H C Spencer
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

3.  A sensitive repetitive DNA probe that is specific to the Leishmania donovani complex and its use as an epidemiological and diagnostic reagent.

Authors:  M K Howard; J M Kelly; R P Lane; M A Miles
Journal:  Mol Biochem Parasitol       Date:  1991-01       Impact factor: 1.759

4.  Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection.

Authors:  E M Carvalho; R S Teixeira; W D Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

5.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

6.  Treatment of murine macrophages with interferon-gamma inhibits their ability to bind leishmania promastigotes.

Authors:  D M Mosser; E Handman
Journal:  J Leukoc Biol       Date:  1992-10       Impact factor: 4.962

Review 7.  The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis.

Authors:  R Badaro; W D Johnson
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

8.  Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.

Authors:  G Harms; K Zwingenberger; B Sandkamp; S Omena; C Pedrosa; J Richter; F Rosenkaimer; H Feldmeier; U Bienzle
Journal:  J Interferon Res       Date:  1993-02

9.  Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis. German Lymphokine Study Group.

Authors: 
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products.

Authors:  N E Reiner; W Ng; W R McMaster
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

View more
  2 in total

1.  Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production.

Authors:  J Li; S Sutterwala; J P Farrell
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

2.  Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis.

Authors:  Sh Jamshidi; R Avizeh; M Mohebali; S Bokaie
Journal:  Iran J Parasitol       Date:  2011-08       Impact factor: 1.012

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.